Photo via Toronto Star

Traferox Technologies Inc. Receives FDA Clearance for the X°Port Heart Preservation System

Read the original at Toronto Star ↗
Cite

Traferox Technologies Inc. Receives FDA Clearance for the X°Port Heart Preservation System. (2026, September 22). Toronto Star. https://www.thestar.com/globenewswire/traferox-technologies-inc-receives-fda-clearance-for-the-x-port-heart-preservation-system/article_3b80d9af-2b1d-520c-b0c9-69a3f5ad177c.html

Dated when The Aporia collected the article, usually within hours of publication. Check the original for its exact date and byline.

Toronto Star · collected 2026-09-22 · by GlobeNewswire, Inc.

Quick Summary

Traferox Technologies Inc., based in Mississauga, Ontario, received FDA clearance on September 22, 2026, for their X°Port® Heart Preservation System. The system allows for static heart preservation at 10°C during transport before transplantation. CEO Rick Mangat emphasized the importance of this approval and highlighted the system's potential to enhance organ preservation and transport practices in transplant centers across the United States.
Written by AI on 2026-09-22, from this article's own text only (the story summary below draws on all the coverage).

AI analysis

Story summary

Traferox Technologies Inc., based in Mississauga, Ontario, received FDA clearance on September 22, 2026 for its X°Port® Heart Preservation System. This device allows hearts to be preserved at a static temperature of 10°C during transport before transplantation. Rick Mangat, the CEO of Traferox, highlighted that this milestone is significant due to the strong clinical evidence supporting 10°C heart preservation and its successful implementation in lung transplant programs. The company aims to collaborate with various transplant centers across the US to further integrate this method into standard practice, potentially enhancing organ preservation and transport efficiency.

Written for “FDA Clears Xport Heart System” on 2026-10-31, grounded in this article and the 0 other(s) covering the same event.

Story

📰 FDA Clears Xport Heart System
Health · 1 article(s) covering the same event.

Compared with similar articles

Nothing to compare against. No article is close enough to this one for the pipeline to have linked or judged the pair.
How this article was measured signals, leaning charts, publisher record, byline, topics and claims

Signals How these are calculated →

Claims extracted
4
sentences that state something as happening or true
Uncertain
0%
0 of 4 hedged ("reportedly", "may", "according to")
Leaning
not political
takes no side on a contested political question
Publisher signals
64/100
Toronto Star's corrections and hedging, across everything collected from it. Not a measure of accuracy.
Outlets on this story
1
Health
Same framing elsewhere
1
articles that frame the event the way this one does
Analyzed 2026-09-22 · how these are computed

How this is being covered How these are calculated →

Article leaning vs. publisher reliability
Source leaning vs. consistency

Publisher

Toronto Star · 10661 article(s) · 27 correction(s) detected
Running correction rate · 27 correction(s)
2026-10-26
Correction
2026-10-24
Correction
2026-10-22
News Clarification for Oct. 22
2026-10-21
No. 6 Hoosiers try to for rare rebound at Michigan after turning the page on 22-game winning streak
2026-10-19
Driver’s License Suspensions for Court Debt Draw Scrutiny
2026-10-16
Amputations and cancer treatment delays: Lawmakers hear testimony on Mississippi prison healthcare
2026-10-16
UPDATE: Golconda Gold Releases Q3 2026 Production Update at Galaxy
2026-10-08
News Clarification for Oct. 8
2026-10-07
Correction
2026-10-05
Entertainment Correction for Oct. 5
2026-10-03
Tennessee's prisons chief is resigning after failed execution of Christa Pike
2026-09-28
Organizations call for Action to End the Deaths of Indigenous People in Custody
2026-09-27
Police memorial recognizes six officers killed in the line of duty in 2026
2026-09-27
UPDATE: WSP to host Power & Energy-focused investor event virtually only
2026-09-26
News Clarification for Sept. 27
2026-09-26
Former federal public servant seeks better pensions for injured workers
2026-09-25
News Corrections for Sept. 25
2026-09-25
She has not been charged. But the Project South allegations have branded her with a 'scarlet letter'
2026-09-24
Correction
2026-09-23
MULTIMEDIA UPDATE: Smith+Nephew launches the new EVOS™ PELVIC Plating System at the 2026 Orthopedic Trauma Association (OTA) Annual Meeting, expanding the EVOS Plating Platform for pelvic and acetabular fracture management
2026-09-22
Costa Rican man complained of lack of care for diabetes before his death in ICE custody, family says
2026-09-22
Judges' grilling of accused men leads to sex assault and dangerous driving cases being overturned
2026-09-20
Jura Energy Corporation Provides Clarification Regarding Media Reports Concerning Its Petroleum Rights in Pakistan
2026-09-19
New details emerge about Toronto's guns-for-hire and the 'crash-out mission" that sparked the Project South investigation
2026-09-17
UPDATE: Osisko Critical Minerals Corporation Announces C$100 Million Private Placement of Special Warrants
2026-09-17
Alabama set to execute man for pawn shop killings months after his nitrogen gas execution blocked
2026-09-04
Orca Corrects Q3 Quarterly Dividend Announcement

Who wrote this

No reporter is named on this article, beyond the feed's “GlobeNewswire, Inc.”.

Topics

FDA GLOBE NEWSWIRE MISSISSAUGA Ontario Traferox

Subjects

FDA ORG · 2× Traferox ORG · 2× GLOBE NEWSWIRE ORG · 1× MISSISSAUGA GPE · 1× Ontario GPE · 1× Rick Mangat PERSON · 1× Traferox Technologies, Inc. ORG · 1× the US Food and Drug Administration ORG · 1×

Narrative

“The strong clinical evidence supporting 10°C heart preservation, together with the successful adoption of 10°C preservation across leading lung transplant programs, has demonstrated the potential of this approach to improve donor organ preservation and transport.
framing: assertive · carried by 1 article(s) · first seen 2026-09-22
2026-09-22 · Toronto Star
Traferox Technologies Inc. Receives FDA Clearance for the X°Port Heart Preservation System · assertive framing

Claims (4 extracted, 0 hedged)

Traferox Technologies, Inc. today announced that the US Food and Drug Administration (FDA) has granted 510(k) clearance for the X°Port® Heart Preservation System, a device that enables static 10°C heart preservation during transport prior to transplantation. asserted
that → announce → transplantation
“The FDA clearance of X°Port Heart marks an important milestone for Traferox and for the continued advancement of 10°C organ preservation,” said Rick Mangat, Chief Executive Officer of Traferox. asserted
Mangat → mark → Traferox
“The strong clinical evidence supporting 10°C heart preservation, together with the successful adoption of 10°C preservation across leading lung transplant programs, has demonstrated the potential of this approach to improve donor organ preservation and transport. asserted
evidence → support → preservation
We look forward to working with transplant centers across the US to support the continued adoption of 10°C preservation in routine clinical practice”. asserted
We → look → practice
💬Give feedback
🕘History 🎫Support
Terms · Privacy · beta v2.0.0
Articles to 31 Oct 2026